Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 48

recruiting
3 972
countries
28
conditions
2 103

1 088 trials match your criteria

Relapsing multiple sclerosis

Not recruiting

Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Fenebrutinib

Colitis ulcerative+1

Not recruiting

A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate

Squamous cell carcinoma of head and neck

Not recruiting

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Small cell lung cancer

Not recruiting

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years

Non-small cell lung cancer

Not recruiting

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab

Thalassaemia beta

Not recruiting

Evaluation of the Efficacy, Safety, and Tolerability of Subcutaneous REGN7999 in Adults with Iron Overload Due to Non-Transfusion Dependent Beta-Thalassemia

Investigational
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:REGN7999

Systemic lupus erythematosus+1

Not recruiting

Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Nonbiologic Standard of Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab

Endometrial cancer recurrent

Not recruiting

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Asthma+1

Not recruiting

Bioequivalence study of fluticasone propionate and salmeterol xinafoate inhalation powder in healthy volunteers for asthma treatment

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · Healthy volunteers
  • Substances:Salmeterol Xinafoate

Lung neoplasm malignant

Not recruiting

Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.